-
Jun 14, 2024 | 
cancernetwork.com | Joshua Richter
June 14, 2024By OncologyONCOLOGY Vol 38, Issue 6Pages: 239-241The June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials. Multiple myeloma (MM) is a plasma cell neoplasm that remains incurable despite significant recent advances in novel and immune-based therapies.1 Although cytogenetic assessment has improved disease classification and prognostication,2 there are no currently approved mutation-targeted agents for myeloma.
-
Apr 11, 2024 | 
nature.com | Joshua Richter
Chimeric antigen receptor T-cell (CAR-T) therapy has become a key option for patients with relapsed and refractory Multiple Myeloma (RRMM). Due to a variety of logistical issues, patients may warrant “bridging” therapy between T-cell leukapheresis and lymphodepleting chemotherapy.
-
Mar 19, 2024 | 
onclive.com | Joshua Richter
Joshua Richter, MD, associate professor of Medicine, the Division of Hematology and Medical Oncology, Tisch Cancer Institute, and director of Multiple Myeloma, Blavatnik Family Chelsea Medical Center, Mount Sinai, discusses ongoing or upcoming research efforts examining bispecific antibodies in earlier lines of therapy for patients with relapsed/refractory multiple myeloma.
-
Mar 12, 2024 | 
onclive.com | Joshua Richter
Dr. Joshua Richter, MD, associate professor of Medicine, the Division of Hematology and Medical Oncology, Tisch Cancer Institute, and director of Multiple Myeloma, Blavatnik Family Chelsea Medical Center, Mount Sinai, discusses the role of bispecific antibodies in the contemporary therapeutic arsenal for patients with relapsed/refractory multiple myeloma.
-
Mar 8, 2024 | 
onclive.com | Joshua Richter
-
Jan 12, 2024 | 
cancernetwork.com | Joshua Richter
Richter: Alright, getting into the homestretch. We touched on a lot today, and I really want to thank all of you so much. But before we get to tallying up the points and giving official bragging rights, 15 seconds each real quick, [what are your] closing thoughts? Dr Usmani, let's start with you. Usmani: The future is bright, and the cure is near. Faiman: How do I beat that? You got it in under 5 seconds and was exactly what I wanted to say. The excitement is real and the energy is palpable.
-
Jan 12, 2024 | 
cancernetwork.com | Joshua Richter
Richter: Now, before I mentioned that we encourage you to talk about yourselves, and I know that's difficult for some of you. But before we close out the day, 1 minute each, please give us your shameless plug from the meeting. The higher you boast, the more points you get—something you presented, something you did, or something for the future. But it has got to focus on you. Dr Usmani, I can think of no one better to start with than you, sir. Usmani: Alright, so this was a big ASH for me personally.
-
Jan 12, 2024 | 
cancernetwork.com | Joshua Richter
Richter: OK, studies aside, the next topic can be on anything out of ASH and it can be anything: trial data, certain drugs, a specific presenter, what they were wearing, the meeting itself—you name it. However, you only have 30 seconds each. So, I really want to know who or what was the biggest winner out of ASH and Dr Faiman, going to go to you first. Faiman: Alright, I have to say it: location, location, location! All of us have our favorite locations for ASH and I like southern California.
-
Jan 6, 2024 | 
cancernetwork.com | Joshua Richter
Richter: Let's keep going on, again, 1 minute each to the 3 of you. What trial was presented that requires the most follow-up as a next step until we can really start using these data? Jeff, of course, I will throw it to you to go first at this time. Matous: Well thank you very much, Mr. Moderator, Dr Richter. I think it's the Immuno-PRISM trial.
-
Jan 6, 2024 | 
cancernetwork.com | Joshua Richter
Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to discuss data from the conference that are most likely to lead to an FDA approval. Richter: Next topic, 1 minute each. We just heard the most practice-changing [data]. But before all of that, what trial is going to lead to the next FDA approval in the soonest time following ASH, or even from any data this year?
